PDSB Stock Analysis: Buy, Sell, or Hold?
PDSB - PDS Biotechnology Corporation Common Stock
$1.25
0.11 (9.65%)
▲
5d:
+27.46%
30d:
+16.82%
90d:
+74.83%
HOLD
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 13, 2026
4d
Get Alerted When PDSB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PDSB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PDSB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PDSB is currently trading at $1.25, which is considered extended relative to its 30-day fair value range of $0.79 to $1.24.
Technical Outlook: Technically, PDSB is in a strong downtrend. The price is approaching resistance at $1.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.50 (+500.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PDSB is in a strong downtrend. The price is approaching resistance at $1.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.50 (+500.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.79 -
$1.24
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.3%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.6%)
- BULLISH: Trading 500.0% below Wall St target ($7.50)
Trading Range Analysis
30-Day Trading Range
$0.79 -
$1.24
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.88
Resistance Level
$1.23
Current Trend
Strong Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.33
Wall Street Target
$7.50
(+500.0%)
Share & Embed Analysis
Last updated: May 08, 2026 6:59 PM ET
Data refreshes hourly during market hours. Next update: 7:59 PM
Data refreshes hourly during market hours. Next update: 7:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PDSB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 55 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$298 | 60 HOLD |
